Expand ALDX Menu
ALDX MENU

ALDX Latest Press Releases

-- March 29, 2026 --

ROSEN, LEADING INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - ALDX Newsfile 12:23 PM

-- March 27, 2026 --

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aldeyra Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - ALDX Newsfile 6:24 PM

-- March 25, 2026 --

ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Overstated Drug Approval Prospects: Levi & Korsinsky PRNewswire 9:01 AM

-- March 24, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX Globe Newswire 5:12 PM
ROSEN, A LEADING NATIONAL FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - ALDX Newsfile 4:01 PM

-- March 23, 2026 --

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - ALDX Newsfile 3:55 PM

-- March 22, 2026 --

ALDX Investor News: If You Have Suffered Losses in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights Globe Newswire 3:53 PM

-- March 21, 2026 --

Rosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - ALDX PRNewswire 1:15 PM

-- March 20, 2026 --

Rosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - ALDX Business Wire 8:16 PM

-- March 19, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX PRNewswire 9:54 PM
ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Drug Efficacy And Approval Prospects: Levi & Korsinsky Globe Newswire 9:00 AM

-- March 18, 2026 --

ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Drug Efficacy And Approval Prospects: Levi & Korsinsky PRNewswire 5:28 PM

-- March 17, 2026 --

$ALDX ALERT: Aldeyra Therapeutics, Inc. Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm Globe Newswire 2:45 PM
Aldeyra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses Globe Newswire 10:54 AM
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease Business Wire 8:30 AM

-- February 18, 2026 --

Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference Business Wire 7:01 AM

-- December 15, 2025 --

Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease Business Wire 7:30 PM

-- November 13, 2025 --

Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast Business Wire 7:00 AM

-- November 11, 2025 --

Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London Business Wire 7:01 AM

-- November 6, 2025 --

Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET Business Wire 7:00 AM
Market Data Delayed 15 Minutes